08/31/2026
We have an incredible NPF family, that are doing big things for the future of Pancreas Cancer and Pancreatitis patients. Dr. Eileen O'Reilly, Chair of our NPF Board of Directors, led the pivotal clinical trial behind the FDA approval of Rasonque (daraxonrasib). ๐๐๐
The FDA has approved daraxonrasib, which will be sold under the brand name Rasonque, for patients with metastatic pancreatic adenocarcinoma who no longer respond to at least one other form of treatment or are not candidates for multiagent systemic therapy.
MSK gastrointestinal medical oncologist Dr. Eileen O'Reilly led the phase 3 clinical trial at MSK that resulted in the approval. The study found that daraxonrasib doubled median survival time compared with chemotherapy, while patients also tolerated its side effects better.
โTo date in my career, I have not seen this level of benefit from any single anti-cancer drug in this disease,โ says Dr. OโReilly.
The targeted therapy blocks KRAS mutations, which drive more than 90% of pancreatic cancers. Learn more about the approval and what it could mean for patients: https://bit.ly/4wLLX3p